Serious vaccine risks accepted by FDA
June 2, 2025
125,133
13,032
2,589
12.48%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Dr John Campbell Episodes Around June 2, 2025
See what was published immediately before and after this episode.
16:02Now PlayingSerious vaccine risks accepted by FDA
YouTube Description
as posted by the channelSerious Adverse Events
MNEXSPIKE group
Serious adverse events were reported by 2.7% of participants (n=156)
Comparator vaccine
Serious adverse events were reported by and 2.6% of participants (n=151)
(median follow-up of 8.8 months).
Targeted approach against the JN.1 variant
Participants received either mRNA-1283 or mRNA-1273.
mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older,
a 13.5% higher rVE in adults aged 65 and older.
CONTRAINDICATIONS
Do not administer MNEXSPIKE to individuals with a known history of severe allergic reaction
Myocarditis and Pericarditis,
increased risks of myocarditis and pericarditis,
risk has been highest in males 12 years through 24 years of age.
Onset of symptoms typically in the first week following vaccination
Although some individuals with myocarditis and/or pericarditis following administration of mRNA COVID-19 vaccines have required intensive care support,
available data suggest that individuals typically have resolution of symptoms within a few days with conservative management.
In hospitalized patients who had been diagnosed with COVID-19 vaccine-associated myocarditis,
Most of these patients had received a two-dose primary series of an mRNA COVID-19 vaccine prior to their diagnosis.
In this study,
)003882/fulltext
at a median follow-up of approximately 5 months post-vaccination, persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common.
The clinical and prognostic significance of these CMR findings is not known
Information is not yet available about potential long-term sequelae of myocarditis or pericarditis following administration of mRNA COVID-19 vaccines.
5.3 Syncope
Syncope (fainting) may occur in association with administration of injectable vaccines.
5.4 Altered Immunocompetence
Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to MNEXSPIKE
5.5 Limitations of Vaccine Effectiveness
MNEXSPIKE may not protect all vaccine recipients.
6 ADVERSE REACTIONS
Most commonly (≥10%) reported adverse reactions following administration of MNEXSPIKE:
Links & Promotions
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.